7EOW
 
 | |
7DHA
 | | crystal structure of CD38 in complex with daratumumab | | 分子名称: | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1, Heavy Chain, Light chain | | 著者 | Lee, H.T, Heo, Y.S. | | 登録日 | 2020-11-13 | | 公開日 | 2021-09-22 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2.55 Å) | | 主引用文献 | Crystal structure of CD38 in complex with daratumumab, a first-in-class anti-CD38 antibody drug for treating multiple myeloma.
Biochem.Biophys.Res.Commun., 536, 2021
|
|
5X8M
 | | PD-L1 in complex with durvalumab | | 分子名称: | Programmed cell death 1 ligand 1, durvalumab heavy chain, durvalumab light chain | | 著者 | Heo, Y.S, Lee, H.T. | | 登録日 | 2017-03-03 | | 公開日 | 2017-08-16 | | 実験手法 | X-RAY DIFFRACTION (2.661 Å) | | 主引用文献 | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Sci Rep, 7, 2017
|
|
5X8L
 | | PD-L1 in complex with atezolizumab | | 分子名称: | Programmed cell death 1 ligand 1, atezolizumab heavy chain, atezolizumab light chain | | 著者 | Heo, Y.S, Lee, H.T. | | 登録日 | 2017-03-03 | | 公開日 | 2017-08-16 | | 実験手法 | X-RAY DIFFRACTION (3.1 Å) | | 主引用文献 | Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
Sci Rep, 7, 2017
|
|
7BXA
 | | Crystal structure of PD-1 in complex with tislelizumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S, Lee, S.H, Lim, H, Lee, H.T, Kim, Y.J, Park, E.B. | | 登録日 | 2020-04-18 | | 公開日 | 2020-06-10 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (3.32 Å) | | 主引用文献 | Crystal structure of PD-1 in complex with an antibody-drug tislelizumab used in tumor immune checkpoint therapy.
Biochem.Biophys.Res.Commun., 527, 2020
|
|
3JBI
 | | MDFF model of the vinculin tail domain bound to F-actin | | 分子名称: | ADENOSINE-5'-DIPHOSPHATE, Actin, alpha skeletal muscle, ... | | 著者 | Kim, L.Y, Thompson, P.M, Lee, H.T, Pershad, M, Campbell, S.L, Alushin, G.M. | | 登録日 | 2015-09-02 | | 公開日 | 2015-11-04 | | 最終更新日 | 2024-02-21 | | 実験手法 | ELECTRON MICROSCOPY (8.5 Å) | | 主引用文献 | The Structural Basis of Actin Organization by Vinculin and Metavinculin.
J.Mol.Biol., 428, 2016
|
|
3JBK
 | | Cryo-EM reconstruction of the metavinculin-actin interface | | 分子名称: | ADENOSINE-5'-DIPHOSPHATE, Actin, alpha skeletal muscle, ... | | 著者 | Kim, L.Y, Thompson, P.M, Lee, H.T, Pershad, M, Campbell, S.L, Alushin, G.M. | | 登録日 | 2015-09-03 | | 公開日 | 2015-11-04 | | 最終更新日 | 2024-02-21 | | 実験手法 | ELECTRON MICROSCOPY (8.2 Å) | | 主引用文献 | The Structural Basis of Actin Organization by Vinculin and Metavinculin.
J.Mol.Biol., 428, 2016
|
|
3JBJ
 | | Cryo-EM reconstruction of F-actin | | 分子名称: | ADENOSINE-5'-DIPHOSPHATE, Actin, alpha skeletal muscle, ... | | 著者 | Kim, L.Y, Thompson, P.M, Lee, H.T, Pershad, M, Campbell, S.L, Alushin, G.M. | | 登録日 | 2015-09-03 | | 公開日 | 2015-11-04 | | 最終更新日 | 2024-02-21 | | 実験手法 | ELECTRON MICROSCOPY (7.6 Å) | | 主引用文献 | The Structural Basis of Actin Organization by Vinculin and Metavinculin.
J.Mol.Biol., 428, 2016
|
|
1ZOI
 | | Crystal Structure of a Stereoselective Esterase from Pseudomonas putida IFO12996 | | 分子名称: | esterase | | 著者 | Elmi, F, Lee, H.T, Huang, J.Y, Hsieh, Y.C, Wang, Y.L, Chen, Y.J, Shaw, S.Y, Chen, C.J. | | 登録日 | 2005-05-13 | | 公開日 | 2006-05-02 | | 最終更新日 | 2024-03-13 | | 実験手法 | X-RAY DIFFRACTION (1.6 Å) | | 主引用文献 | Stereoselective esterase from Pseudomonas putida IFO12996 reveals alpha/beta hydrolase folds for D-beta-acetylthioisobutyric acid synthesis
J.Bacteriol., 187, 2005
|
|
7WWP
 | | Crystal structure of human Npl4 | | 分子名称: | Nuclear protein localization protein 4 homolog, ZINC ION | | 著者 | Nguyen, T.Q, Le, L.T.M, Kim, D.H, Ko, K.S, Lee, H.T, Nguyen, Y.T.K, Kim, H.S, Han, B.W, Kang, W, Yang, J.K. | | 登録日 | 2022-02-14 | | 公開日 | 2022-09-21 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (2.99 Å) | | 主引用文献 | Structural basis for the interaction between human Npl4 and Npl4-binding motif of human Ufd1.
Structure, 30, 2022
|
|
7WWQ
 | | Crystal structure of human Ufd1-Npl4 complex | | 分子名称: | Nuclear protein localization protein 4 homolog, Ubiquitin recognition factor in ER-associated degradation protein 1 | | 著者 | Nguyen, T.Q, Le, L.T.M, Kim, D.H, Ko, K.S, Lee, H.T, Nguyen, Y.T.K, Kim, H.S, Han, B.W, Kang, W, Yang, J.K. | | 登録日 | 2022-02-14 | | 公開日 | 2022-09-21 | | 最終更新日 | 2024-05-29 | | 実験手法 | X-RAY DIFFRACTION (2.72 Å) | | 主引用文献 | Structural basis for the interaction between human Npl4 and Npl4-binding motif of human Ufd1.
Structure, 30, 2022
|
|
6JC2
 | | Crystal structure of the Fab fragment of ipilimumab | | 分子名称: | SULFATE ION, ipilimumab fab heavy chain, ipilimumab fab light chain | | 著者 | Heo, Y.S. | | 登録日 | 2019-01-27 | | 公開日 | 2019-09-11 | | 実験手法 | X-RAY DIFFRACTION (2.65 Å) | | 主引用文献 | Crystal Structure of the Fab Fragment of an Anti-CTLA-4 Antibody, Ipilimumab, Used for Cancer Immunotherapy
Bull.Korean Chem.Soc., 40, 2019
|
|
5GGU
 | | Crystal structure of tremelimumab Fab | | 分子名称: | heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (2.292 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGS
 | | PD-1 in complex with pembrolizumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.997 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGV
 | | CTLA-4 in complex with tremelimumab Fab | | 分子名称: | Cytotoxic T-lymphocyte protein 4, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.998 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGT
 | | PD-L1 in complex with BMS-936559 Fab | | 分子名称: | IGK@ protein, IgG H chain, Programmed cell death 1 ligand 1 | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2024-03-20 | | 実験手法 | X-RAY DIFFRACTION (2.8 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGQ
 | | Crystal structure of Nivolumab Fab fragment | | 分子名称: | nivolumab heavy chain, nivolumab light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5GGR
 | | PD-1 in complex with nivolumab Fab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2016-06-16 | | 公開日 | 2016-11-09 | | 最終更新日 | 2016-11-16 | | 実験手法 | X-RAY DIFFRACTION (3.3 Å) | | 主引用文献 | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy
Nat Commun, 7, 2016
|
|
5Y9J
 | | BAFF in complex with belimumab | | 分子名称: | Tumor necrosis factor ligand superfamily member 13B, belibumab light chain, belimumab heavy chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (2.05 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
5Y9K
 | | Structure of the belimumab Fab fragment | | 分子名称: | belimumab heavy chain, belimumab light chain | | 著者 | Heo, Y.-S, Shin, W. | | 登録日 | 2017-08-25 | | 公開日 | 2018-02-21 | | 最終更新日 | 2019-09-04 | | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | | 主引用文献 | BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
Nat Commun, 9, 2018
|
|
2LCI
 | | Solution NMR Structure of DE NOVO DESIGNED PROTEIN, P-LOOP NTPASE FOLD, Northeast Structural Genomics Consortium Target OR36 (CASD Target) | | 分子名称: | Protein OR36 | | 著者 | Liu, G, Koga, N, Koga, R, Xiao, R, Janjua, H, Ciccosanti, C, Lee, H, Acton, T.B, Everett, J, Baker, D, Montelione, G.T, Northeast Structural Genomics Consortium (NESG) | | 登録日 | 2011-04-29 | | 公開日 | 2011-06-29 | | 最終更新日 | 2024-05-15 | | 実験手法 | SOLUTION NMR | | 主引用文献 | Northeast Structural Genomics Consortium Target OR36
To be Published
|
|
1F5Y
 | | NMR STRUCTURE OF A CONCATEMER OF THE FIRST AND SECOND LIGAND-BINDING MODULES OF THE HUMAN LDL RECEPTOR | | 分子名称: | CALCIUM ION, LOW-DENSITY LIPOPROTEIN RECEPTOR | | 著者 | Kurniawan, N.D, Atkins, A.R, Brereton, I.M, Kroon, P.A, Smith, R. | | 登録日 | 2000-06-18 | | 公開日 | 2000-08-30 | | 最終更新日 | 2022-02-16 | | 実験手法 | SOLUTION NMR | | 主引用文献 | NMR structure of a concatemer of the first and second ligand-binding modules of the human low-density lipoprotein receptor.
Protein Sci., 9, 2000
|
|
7WSL
 | | PD-1 in complex with Dostarlimab | | 分子名称: | Programmed cell death protein 1, heavy chain, light chain | | 著者 | Heo, Y.S. | | 登録日 | 2022-01-30 | | 公開日 | 2022-08-24 | | 最終更新日 | 2023-11-29 | | 実験手法 | X-RAY DIFFRACTION (1.534 Å) | | 主引用文献 | Molecular basis of PD-1 blockade by dostarlimab, the FDA-approved antibody for cancer immunotherapy.
Biochem.Biophys.Res.Commun., 599, 2022
|
|
